CO141 Evaluating the Impact of Luxturna Gene Therapy on Vision Improvement and Disease Progression in Patients With RPE65 Mutation-Associated Inherited Vision Loss
Human medicines European public assessment report (EPAR): Luxturna, voretigene neparvovec, Leber Congenital Amaurosis,Retinitis Pigmentosa, Date of authorisation: 22/11/2018, Revision: 1, Status: Authorised
History and Development Story of Luxturna: Scientific and Regulatory Challenges
3 BLAs in 3 Years: Ocugen Sees Potential in Eye Disease Gene Therapies: Company aims to succeed where Luxturna failed in achieving commercial success by treating blindness-related diseases
TERAPIA GÉNICA EN ENFERMEDADES RARAS DE LA RETINA: AVANCES TRAS LOS PRIMEROS AÑOS DE IMPLEMENTACIÓN DE FÁRMACOS COMO EL LUXTURNA.
